Advertisement

Topics

Vectura asthma inhaler makes "positive" regulatory progress in Europe

13:21 EDT 4 Oct 2017 | Reuters
Related Biotechnology, Pharmaceutical and Healthcare News

(Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favorable regulatory progress in Europe, and it can now apply for approvals through its partner.

Original Article: Vectura asthma inhaler makes "positive" regulatory progress in Europe

NEXT ARTICLE

More From BioPortfolio on "Vectura asthma inhaler makes "positive" regulatory progress in Europe"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.